Hone Health, Maximus, and the Enclomiphene DTC Startups
Marketing Claims vs. Evidence for DTC TRT and Enclomiphene Players
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Enclomiphene is NOT FDA-approved for low testosterone; sold off-label via compounding
Reference only. Not medical advice.
What can go wrong
Enclomiphene is unapproved for this use; long-term safety data are limited and it is dispensed via compounding without FDA manufacturing oversight. SERMs can cause visual disturbances, mood effects, and other adverse events. Marketing that presents internal white-paper multiples as established efficacy can overstate the evidence and understate that this is off-label, compounded use of an FDA-rejected molecule.
This is something to take to a clinician. The Atlas can tell you what is known about hone health, maximus, and the enclomiphene dtc startups in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Hone Health and Maximus (Maximus Tribe) are DTC telehealth startups in the testosterone space. Hone Health markets at-home testing and direct TRT; Maximus describes 'oral TRT+' protocols built around enclomiphene, a selective estrogen receptor modulator that raises endogenous testosterone while tending to preserve fertility. Importantly, enclomiphene is NOT FDA-approved for low testosterone, its developer Repros Therapeutics' application was rejected, so it is sold off-label and through compounding. Maximus has published its own internal white-paper data (around 79 participants) reporting large testosterone increases, which is company-generated, not independent peer-reviewed evidence.
Internal white papers and 4x claims; an FDA-rejected molecule.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Enclomiphene blocks estrogen feedback at the hypothalamus/pituitary, raising LH and FSH and thereby stimulating the testes to produce more testosterone, distinct from exogenous TRT, which suppresses the axis. Because it works upstream, it tends to preserve spermatogenesis, which is the basis of the 'fertility-friendly' marketing. It only works if the testes can still respond; in primary testicular failure there is nothing to stimulate.
The Catch: Company Data Is Not Independent Evidence
The independent literature reasonably supports enclomiphene raising testosterone in men with secondary hypogonadism while preserving fertility markers. What is weaker is the leap from that to a specific brand's protocol: Maximus's headline figures come from its own ~79-participant white paper, not independent peer review, and the molecule itself failed to win FDA approval. 'Clinically studied' in marketing can mean 'the company studied its own product.'
What it does to fertility
Enclomiphene's selling point is fertility preservation: by raising endogenous LH/FSH it stimulates rather than suppresses spermatogenesis, in contrast to exogenous testosterone. This is genuinely supported in secondary-hypogonadism literature, though long-term and brand-specific data remain limited.
What people get wrong
Often saidMaximus's protocol is proven to multiply your testosterone 4-5x
ActuallyThose multiples come from Maximus's own ~79-person white paper, not independent peer review; enclomiphene generally raises T in secondary hypogonadism, but the specific branded protocol is not independently validated and the molecule is not FDA-approved for this use.
Often saidEnclomiphene is an FDA-approved TRT alternative
ActuallyIt is not FDA-approved for low testosterone, Repros Therapeutics' application was rejected, so it is prescribed off-label and via compounding.
Who profits, and who pushes back
FDA / regulatory record
Did not approve enclomiphene (Androxal) for hypogonadism; the Repros Therapeutics application was rejected, leaving the molecule off-label.
The startups, their prescribers, the compounding pharmacies supplying enclomiphene, and the at-home lab vendors.
What we do not know
- Will any company complete the independent RCTs and FDA process enclomiphene's marketing implies already exists?
- How do long-term safety outcomes of chronic enclomiphene compare to conventional TRT?
At a glance
- Enclomiphene FDA status
- Not approved for low T (Repros application rejected)
- Maximus internal data
- Company white paper, ~79 participants, ~4x total-T / ~5x free-T claimed
- Hone Health model
- At-home testing + direct TRT
- Independent evidence
- Enclomiphene does raise T in secondary hypogonadism in peer-reviewed studies, but not the specific branded protocols
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Hone Health, Maximus, and the Enclomiphene DTC Startups. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.